This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for Type 1 Diabetes(T1D).

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.

JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. has provided $120,000 in support of two CCTN Post-Doctoral Fellows for one year in the sum of $60,000 each.

Helmsley’s Type 1 Diabetes Program has launched a Request for Proposals – the Future Technologies Initiative (FTI). The goal of the FTI is to incubate proof-of-concept, early-stage research and development in the following two tracks: